|Bid||3.30 x 300|
|Ask||4.00 x 3000|
|Day's Range||3.35 - 3.55|
|52 Week Range||2.35 - 4.49|
|PE Ratio (TTM)||-0.47|
|Earnings Date||Aug 2, 2017 - Aug 8, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||7.53|
Combinations of Arbutus’ RNAi or Capsid Assets with Approved Drugs Demonstrate Complementary Activity Dr. Michael J. Sofia, Arbutus’ Chief Scientific Officer, Awarded International Society of Antiviral ...
“We have seen no evidence of a Moderna delivery system that is free of our intellectual property. Not in their publications, their presentations, or in the examples in their patent filings,” said Mark Murray, in his first interview on the subject.
Q1 2017 Arbutus Biopharma Corp Earnings Call